Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity

Blood

Volumn 101, Issue 11, 2003, Pages 4485-4491

  Zeng, Yi ^b   Feng, Hanping ^b   Graner, Michael W ^b   Katsanis, Emmanuel ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CHAPERONE; HLA ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL LYSATE; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOSTIMULATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CELL FREE SYSTEM; IMMUNOLOGY; LEUKEMIA; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CELL-FREE SYSTEM; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LEUKEMIA; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MOLECULAR CHAPERONES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0038466354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3108     Document Type: Article

References (38)

1. Srivastava PK, Maki RG. Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol. 1991;167:109-123.
2. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol. 1994;152:5398-5403.
3. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res. 2000;6:909-915.
4. Heike M, Noll B, Meyer zum Buschenfelde KH. Heat shock protein-peptide complexes for use in vaccines. J Leukoc Biol. 1996;60:153-158.
5. Arnold D, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med. 1995;182:885-889.
6. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178:1391-1396.
7. Graner M, Raymond A, Akpodaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother. 2000;49:476-484.
8. Fields RC, Osterholzer JJ, Fuller JA, Thomas EK, Geraghty PJ, Mule JJ. Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J Immunother. 1998;21:323-339.
9. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of murine T cell surface molecule designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J Immunol. 1983;131:2445-2453.
10. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol. 1980;125:2665-2673.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Roy Stat Soc. 1972;A135:185-207.
13. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14:303-313.
14. Forsdyke DR. Heat shock proteins as mediators of aggregation-induced 'danger' signals: implications of the slow evolutionary fine-tuning of sequences for the antigenicity of cancer cells. Cell Stress Chaperones. 1999;4:205-210.
15. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998;4:581-587.
16. Todryk S, Melcher AA, Hardwick N, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol. 1999;163:1398-1408.
17. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol. 2000;12:1539-1546.
18. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c(+) cells in vivo. J Immunol. 2000;165:6029-6035.
19. + cells. J Immunol. 2000;165:2582-2587.
20. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6:435-442.
21. Singh-Jasuja H, Hilf N, Scherer HU, et al. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones. 2000;5:462-470.
22. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
23. He L, Feng H, Raymond A, et al. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother. 2001;50:31-40.
24. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001;97:3505-3512.
25. Arnold-Schild D, Hanau D, Spehner D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999;162:3757-3760.
26. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol. 1999;162:1303-1309.
27. Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med. 2000;191:1957-1964.
28. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000;191:1965-1974.
29. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem. 2001;276:17163-17171.
30. Binder RJ, Karimeddini D, Srivastava PK. Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91. J Immunol. 2001;166:4968-4972.
31. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000;1:151-155.
32. Shimizu K, Fields RC, Redman BG, Giedlin M, Mule JJ. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am. 2000;6(suppl 1):S67-S75.
33. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
34. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother. 2003;52:226-234.
35. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann Rev Immunol. 2002;20:395-425.
36. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood. 2003;101:245-252.
37. Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med. 1999;189:797-802.
38. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol. 1999;162:6426-6432.